Diabetes has reached epidemic proportions in the United States resulting in expenditures of over $90B per year. The enormity of the potential market inspired many pharmaceutical companies to enter the field but success has proven difficult. The reason for this difficulty is that diabetes is a complicated disease affecting multiple organ systems including the kidneys, nervous system, and vascular system. The most severe effects of diabetes are related to long-term toxicity of high circulating glucose levels. Glucose toxicity and insulin resistance remain the greatest unmet need in the treatment of diabetes. Further, the chronic nature of diabetes requires that therapeutics present long-term safety profiles, a serious obstacle to clinical and market success. MEDROS'goal is to impact the field of diabetes by providing drugs that ameliorate the effects of insulin resistance using a different approach to drug discovery. MEDROS was founded on a proprietary platform optimized for high-throughput drug screening in situ by generating human diseases in the fruit fly Drosophila. Our whole-organism approach holds the promise of producing better safety and efficacy data than traditional pre-clinical modeling techniques with lower cost. MEDROS has licensed screening technology, from our academic collaborators at Washington University, regarding a diet-induced Drosophila model system for insulin resistance and Type-2 diabetes mellitus (T2DM). This model, achieved by feeding flies a high sugar diet, phenocopies important physiology observed in human patients with T2DM, namely hyperglycemia, hyperinsulinemia, and triglyceride accumulation, and also recapitulates the endpoint outcome- shortened lifespan. However, measurement of these endpoints is not conducive to high-throughput testing so modifications of this system are required for compound screening. At MEDROS we have successfully expanded on our founders'work and created a cancer fly model where flies die during a discreet point in their development by over-expressing oncogenes providing a rescue-from-lethality screening readout. The objective for this Phase I SBIR proposal is to apply this same approach to our diabetes research. In Aim 1 we will create transgenic fly lines with tunable expression levels of genes required for survival on a high sugar diet (i.e. insulin receptor, or Chico, etc) and optimize this system so that flies die during pupal development. In Aim 2 we will screen our compound collection in a 96-well format in search of molecules that yield adult flies. These compounds will be processed through our relevant secondary assays to quantify biochemical markers to establish relevance to the human disease. MEDROS'ultimate vision is to validate an entirely whole organism approach to diabetes drug discovery. , ,
Public Health Relevance: Diabetes has reached epidemic proportions in the United States, resulting in expenditures approaching $100 billion per year. Glucose toxicity and insulin resistance remain perhaps the greatest unmet need in the treatment of diabetes. MEDROS owns a proprietary Drosophila model that displays metabolic defects that mimic those in patients with T2DM: hyperglycemia, hyperinsulinemia, triglyceride accumulation, and shortened lifespan. MEDROS'goal is to impact the field of diabetes not only by putting better drugs into the clinic, but also by developing a different approach to drug discovery utilizing high-throughput whole-organism drug screens in fruit flies with human-like diseases.
Thesaurus Terms: 21+ Years Old;Address;Adult;Affect;Applications Grants;Area;Assay;Belief;Bioassay;Biochemical Markers;Biologic Assays;Biological Assay;Biological Models;Body Tissues;Cancer Genes;Cancer-Promoting Gene;Cancers;Cell Communication And Signaling;Cell Signaling;Chimera;Chimera Organism;Chronic;Clinic;Clinical;Collection;D-Glucose;Data;Defect;Development;Dextrose;Diabetes Mellitus;Diabetes Mellitus, Adult-Onset;Diabetes Mellitus, Ketosis-Resistant;Diabetes Mellitus, Non-Insulin-Dependent;Diabetes Mellitus, Noninsulin Dependent;Diabetes Mellitus, Slow-Onset;Diabetes Mellitus, Stable;Diabetes Mellitus, Type 2;Diabetes Mellitus, Type Ii;Diet;Disease;Disease Model;Disorder;Drosophila;Drosophila Genus;Drug Evaluation, Preclinical;Drug Industry;Drug Screening;Drugs;Effectiveness;Enzymes;Epidemic;Evaluation;Evaluation Studies, Drug, Pre-Clinical;Evaluation Studies, Drug, Preclinical;Expenditure;Flies;Fruit Fly, Drosophila;Gene Down-Regulation;Gene Expression;Genes;Genetic Screening;Glucose;Goals;Grant Proposals;Grants, Applications;High Throughput Assay;Human;Human, Adult;Human, General;Hyperglycemia;Hyperinsulinemia;Hyperinsulinism;Insr;In Situ;In Vitro;Industry, Pharmaceutic;Insulin Receptor;Insulin Receptor Protein-Tyrosine Kinase;Insulin Resistance;Insulin-Dependent Tyrosine Protein Kinase;Intracellular Communication And Signaling;Kidney;Legal Patent;Length Of Life;Licensing;Longevity;Mody;Malignant Neoplasms;Malignant Tumor;Man (Taxonomy);Man, Modern;Marketing;Maturity-Onset Diabetes Mellitus;Measurement;Mediating;Medication;Metabolic;Methods;Methods And Techniques;Methods, Other;Model System;Modeling;Models, Biologic;Modification;Niddm;Nrvs-Sys;Nature;Nervous System;Nervous System Structure;Neurologic Body System;Neurologic Organ System;Non-Insulin Dependent Diabetes;Non-Insulin-Dependent Diabetes Mellitus;Oncogenes;Organ System;Organism;Outcome;Patents;Patients;Pharmaceutic Preparations;Pharmaceutical Agent;Pharmaceutical Industry;Pharmaceutical Preparations;Pharmaceuticals;Pharmacologic Substance;Pharmacological Substance;Pharmacology;Phase;Phenocopy;Physiology;Post-Transcriptional Gene Silencing;Post-Transcriptional Gene Silencings;Posttranscriptional Gene Silencing;Posttranscriptional Gene Silencings;Pre-Clinical Model;Preclinical Drug Evaluation;Preclinical Models;Process;Progesterone Receptors;Quelling;R 38486;R38486;Ras Family Oncogene;Rna Interference;Rna Silencing;Rna Silencings;Rnai;Ru-38486;Ru-486;Ru38486;Ru486;Receptors, Progesterone;Receptors, Progestin;Regulation;Research;Retrovirus Associated Sequence Oncogene;Sbir;Sbirs (R43/44);Safety;Screening Procedure;Sequence-Specific Posttranscriptional Gene Silencing;Sight;Signal Transduction;Signal Transduction Systems;Signaling;Small Business Innovation Research;Small Business Innovation Research Grant;Statistical Study;Switch Genes;System;System, Loinc Axis 4;T2d;T2dm;Techniques;Technology;Testing;Therapeutic;Tissues;Toxic Effect;Toxicities;Toxicology;Transcription Repression;Transcriptional Repression;Transforming Genes;Transgenes;Transgenic Organisms;Triacylglycerol;Triglycerides;Type 2 Diabetes;Type Ii Diabetes;United States;Universities;Urinary System, Kidney;Vascular System;Vision;Washington;Whole Organism;Work;Adult Human (21+);Adult Onset Diabetes;Biological Signal Transduction;Body System;Combat;Cost;Diabetes;Disease/Disorder;Disorder Model;Drug Discovery;Drug/Agent;Feeding;Fly;Fruit Fly;Gene Repression;High Throughput Screening;Human Disease;Hyperglycemic;Improved;Inhibitor;Inhibitor/Antagonist;Insulin Resistant;Ketosis Resistant Diabetes;Knock-Down;Life Span;Lifespan;Living System;Malignancy;Maturity Onset Diabetes;Medical Schools;Neoplasm/Cancer;Novel;Pre-Clinical;Preclinical;Progesterone Receptor;Public Health Relevance;Ras Oncogene;Renal;Screening;Screenings;Success;Sugar;Transgenic
